Is RXRX or SEER more undervalued in 2026?

CirclFi compares Recursion Pharmaceuticals, Inc. (RXRX) and Seer, Inc. (SEER) using 13 institutional-grade valuation models. RXRX has a Quality of Company score of 6.5/10 while SEER scores 6.9/10.

Which is a better buy — RXRX or SEER?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RXRX and SEER valuations compare?

RXRX at $3.44 and SEER at $1.93 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RXRX vs SEER Valuation Comparison 2026 — Intrinsic Value Analysis

RXRX

Biotechnology

Recursion Pharmaceuticals, Inc.

Quality

6.5

out of 10

Value Trap

LOW

Price

$3.44

Last close

Models

9/13

Active

SEER

Biotechnology

Seer, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$1.93

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	RXRX Fair Value	RXRX Upside	SEER Fair Value	SEER Upside
Bayesian DCF	Intrinsic	$1.52	-55.8%	$0.82	-57.6%
Earnings Power Value	Intrinsic	—	—	$1.11	-42.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.99	-42.2%	$3.24	+68.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RXRX vs SEER — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RXRX vs SEER — Which Stock Is More Undervalued?

SEER scores higher with a 6.9/10 quality rating vs RXRX's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Recursion Pharmaceuticals, Inc. (RXRX) and Seer, Inc. (SEER) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RXRX currently trades at $3.44 with a QOC of 6.5/10, while SEER trades at $1.93 with a QOC of 6.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).